Extended Data Table 2 Frequency of aGVHD by organ involvement and maximum MAGIC criteria

From: Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial

  1. Analysis included all randomized patients who received ≥1 dose of study treatment and allo-HSCT. Confidence interval (CI) was based on the Clopper-Pearson method.
  2. Allo-HSCT, allogeneic hematopoietic stem cell transplantation; MAGIC, Mount Sinai Acute GVHD International Consortium (Harris AC, et al. Biol Blood Marrow Transplant 2016;22:4-10).
Back to article page